Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. - Wikidata - wikimedia - TriplyDB

Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties.

Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties.

http://www.wikidata.org/entity/Q37031056

about

Effect of Pharmacological Modulation of the Endocannabinoid System on Opiate Withdrawal: A Review of the Preclinical Animal Literature Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system Decreased reward sensitivity in rats from the Fischer344 strain compared to Wistar rats is paralleled by differences in endocannabinoid signaling 2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s).Local pretreatment with the cannabinoid CB1 receptor antagonist AM251 attenuates methamphetamine intra-accumbens self-administration.Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review.Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior An Internet survey of marijuana and hot shower use in adults with cyclic vomiting syndrome (CVS).Analysis of tolerance and behavioral/physical dependence during chronic CB1 agonist treatment: effects of CB1 agonists, antagonists, and noncannabinoid drugs.The endocannabinoid system in brain reward processes Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors.Critical appraisal of the potential use of cannabinoids in cancer management.Screening Medications for the Treatment of Cannabis Use Disorder.The endocannabinoid system: a new molecular target for the treatment of tobacco addiction.The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).Cannabinoid-Induced Hyperemesis: A Conundrum-From Clinical Recognition to Basic Science Mechanisms.Synthetic Pot: Not Your Grandfather's Marijuana.Effects of a novel CB1 agonist on visual attention in male rats: role of strategy and expectancy in task accuracy.Behavioral effects of the novel potent cannabinoid CB1 agonist AM 4054.The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats.CB1 antagonism: interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats.Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk.The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs.

P2860

Q26738333-5638F34F-A3B9-44F5-BD4C-8866268855B2 Q26783956-B2603D2E-66D9-4064-AB7C-38A06E90E95A Q28241318-0F3726D4-9735-42E9-A41E-A6FBEE1B709F Q28301264-4A3BAF3C-3FB9-4881-99AA-5E4C0E82DD30 Q30470474-0D5E7C90-C05A-4212-8DE2-351C02ECE290 Q33781776-0A6F2528-C6BD-458A-8F73-702970E533ED Q34500324-2ED8191E-671F-4540-B654-EDBD8961CB17 Q34543977-36876F38-05CC-4113-8305-956D37829127 Q34545629-73227843-759C-4A30-914B-610FA39FAEDF Q34547759-796E37DA-9A1F-4096-B143-1A0F2B20B5C6 Q35532072-B1E23FF7-C9AE-45E6-AEAD-D0635B1599A6 Q35626920-ACB7D426-0D69-4DD4-8DEC-2811DEED0CD7 Q35785005-4A1D9F59-6A3E-4431-AF1D-2246A51B2281 Q36157783-BC91E16F-4A4A-4E13-8C5C-7FC27E222D73 Q36270894-2D167157-D8FA-469E-81DE-024A808A4BFF Q36573225-DB91AE13-A2A7-4E90-B57D-6608BCDC1A43 Q36741861-C366ADCE-E7C2-4FE6-BE08-E4908EBB63C4 Q37082410-7677471D-F062-4AED-8911-AC4BD1CE9372 Q37164208-081363B3-9808-4F7C-9DCC-6DC28D063E9E Q37187618-EB47B37C-F668-49C0-BFAF-91DA59E42CFC Q37291517-3A4E0F8F-0945-4529-9DDD-318F0FEB17C1 Q37392290-E36CCA3B-88FF-4102-B5FD-34DD944EAAED Q37899264-EF9A21D2-FF58-418F-B37D-EB2F40DD015A Q38974381-4F1F1699-A248-4BDB-B7D5-7F6D030D9025 Q39120303-C607F5EB-26C9-4328-B440-A656121CF917 Q39121700-9429165D-D55C-495D-A378-509FA4A9E104 Q39417079-3F8125EB-45FF-4BD2-B372-7226AD3ED20F Q41155236-E37175F1-B519-459C-9825-5BE3B161B655 Q42961232-BD23BDAD-D7B7-489F-9B94-73F276E9A159 Q43194095-12ACA1E6-DC02-40A8-A8EE-7139BC82A605 Q45288843-14E13A19-8C19-4E01-8018-05DB68DF7ED5 Q48944762-230A21AE-3B27-4F12-A11A-78FFD46AA38E

P2860

Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties.

http://www.wikidata.org/entity/Q37031056

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties.

@en

Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties.

@nl

type

label

Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties.

@en

Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties.

@nl

prefLabel

Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties.

@en

Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties.

@nl

P1433

Q37031056-7EAF1D07-89FF-4BDA-A607-D14E285C7FA1

P1476

Q37031056-0638245D-23B1-4F50-ACE6-E8059948D875

P2093

Q37031056-0CF65677-B982-407C-B397-6F719A9F58C5

Q37031056-31E0BB80-9329-40E6-9196-C8697A678CD9

Q37031056-46B035BD-0137-4449-9191-7D09C490D34E

Q37031056-74AAB908-38AC-4221-860F-05127E409138

Q37031056-90A5E8CB-26A0-4AD4-8C02-E6D83F3E3DD0

Q37031056-A3B105C6-65CD-401A-B3E8-C5E0AB43F987

P2860

Q37031056-022FF11A-E3E4-4114-8390-3B4D184C9206

Q37031056-174F2833-6361-4957-9444-33EA6AB10E3C

Q37031056-1A97D800-3788-41A2-B2AB-C887CF240CC2

Q37031056-1E17B6AF-6B06-417F-BFE8-6337878281B3

Q37031056-25B01504-1F9F-4D2F-B3C6-418553EB9F17

Q37031056-2997F25E-A4B7-489F-8872-9038FFE1C2A1

Q37031056-34862B80-65CC-4F93-A3A6-5A330F7D5615

Q37031056-353396FE-63C0-4A8A-8AD1-733CB6408A60

Q37031056-4DB5E42F-1BE0-4299-AC28-CD1FCBA27035

Q37031056-585AF038-0637-454F-90C4-FD9AFCA5AF61

P304

Q37031056-B7313282-1B93-4254-8CB8-9C7BE285B7FB

P31

Q37031056-B7C7F829-191A-4389-B749-C663992A2223

P356

Q37031056-8EEE13FA-5ADA-402A-9BBE-4A3E32BBEEF3

P407

Q37031056-FCA97F9E-01B9-4722-82AF-232C52856393

P433

Q37031056-B45DBF38-3503-4E11-B701-A943AE04CAB5

P478

Q37031056-7230FB1B-4D0B-4E68-9058-6482683DA64D

P577

Q37031056-B7CB6019-2099-4A5F-9DC7-713BFFEA611B

P5875

Q37031056-0E9D63EC-EC91-4BE7-94BC-D6A250DBE215

P698

Q37031056-D6AFA13F-37B3-4CC7-9740-3BEBFB7BD1D8

P932

Q37031056-EF70CB00-5CCF-4146-A990-2DCC062EA781

P356

J.PHYSBEH.2007.11.007

P1433

Physiology and Behavior

P1476

Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties.

@en

P2093

Alex Makriyannis

http://www.w3.org/2001/XMLSchema#string

Carol A Paronis

http://www.w3.org/2001/XMLSchema#string

Ganesh A Thakur

http://www.w3.org/2001/XMLSchema#string

Jack Bergman

http://www.w3.org/2001/XMLSchema#string

Kiran Vemuri

http://www.w3.org/2001/XMLSchema#string

Marcus S Delatte

http://www.w3.org/2001/XMLSchema#string

P2860

Differential behavioral effects of low efficacy positive GABAA modulators in combination with benzodiazepines and a neuroactive steroid in rhesus monkeys

Inhibitory effects of SR141716A on G-protein activation in rat brain.

CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats.

An investigation into the structural determinants of cannabinoid receptor ligand efficacy.

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

New approaches for the management of patients with multiple cardiometabolic risk factors.

Conditioned gaping in rats: a selective measure of nausea.

Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients.

Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.

Sarmazenil-precipitated withdrawal: a reliable method for assessing dependence liability of benzodiazepine receptor ligands.

P304

666-670

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PHYSBEH.2007.11.007

http://www.w3.org/2001/XMLSchema#string

P407

P433

4-5

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P577

2007-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5771535

http://www.w3.org/2001/XMLSchema#string

P698

18076956

http://www.w3.org/2001/XMLSchema#string

P932

2441972

http://www.w3.org/2001/XMLSchema#string